Contineum Therapeutics, Inc. (CTNM)
| Market Cap | 306.24M -1.0% |
| Revenue (ttm) | n/a |
| Net Income | -57.56M |
| EPS | -1.72 |
| Shares Out | 37.62M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 402,682 |
| Open | 8.25 |
| Previous Close | 8.31 |
| Day's Range | 8.02 - 8.59 |
| 52-Week Range | 6.73 - 17.79 |
| Beta | 0.86 |
| Analysts | Buy |
| Price Target | 22.14 (+171.99%) |
| Est. Earnings | Nov 6, 2026 |
About CTNM
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitt... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for CTNM stock is "Buy." The 12-month stock price target is $22.14, which is an increase of 171.99% from the latest price.
News
Contineum price target raised to $30 from $24 at Jones
Jones raised the firm’s price target on Contineum (CTNM) to $30 from $24 and keeps a Buy rating on the shares. The firm away from admilparant’s Phase 3 ALOFT-IPF trial…
Contineum downgraded to Neutral from Outperform at Baird
Baird analyst Charles Moore downgraded Contineum (CTNM) to Neutral from Outperform with a price target of $14, down from $19. The company’s hypothesis for greater LPA1R occupancy leading to greater…
Contineum downgraded to Neutral from Outperform at Baird
Baird downgraded Contineum (CTNM) to Neutral from Outperform with a price target of $14, down from $19. Contineum’s hypothesis for greater LPA1R occupancy leading to greater efficacy in idiopathic pul...
Jones sees greater room for Contineum’s PIPE-791 to differentiate
Jones reiterated a Buy rating and $24 price target on Contineum (CTNM) after a competitor report identified a Phase 3 long-term extension protocol amendment that newly classifies liver injury as…
Contineum Therapeutics Inc trading resumes
16:00 EDT Contineum (CTNM) Therapeutics Inc trading resumes
Contineum Therapeutics Inc trading halted, volatility trading pause
15:50 EDT Contineum (CTNM) Therapeutics Inc trading halted, volatility trading pause
Contineum price target lowered to $17 from $18 at Morgan Stanley
Morgan Stanley analyst Sean Laaman lowered the firm’s price target on Contineum (CTNM) to $17 from $18 and keeps an Equal Weight rating on the shares. Following the MOONLIGHT-1 study…
Contineum resumed at Early-Stage Biotech at Goldman Sachs
Goldman Sachs resumed coverage of Contineum (CTNM) with an Early-Stage Biotech rating. Goldman resumed coverage of the biotechnology sector, saying the group has continued to outperform despite a back...
Contineum Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
China-origin innovation and AI are driving efficiency and new BD opportunities. PIPE-791, a once-daily LPA1R antagonist for IPF, is differentiated by its lack of dose titration and strong receptor occupancy. The company is funded through mid-2029, focusing on PROPEL-IPF while monitoring the evolving competitive landscape.
Contineum price target lowered to $24 from $26 at Jones
Jones lowered the firm’s price target on Contineum (CTNM) to $24 from $26 and keeps a Buy rating on the shares. PIPE-307 was well-tolerated but didn’t hit the primary endpoint…
Contineum price target lowered to $19 from $20 at Baird
Baird lowered the firm’s price target on Contineum (CTNM) to $19 from $20 and keeps an Outperform rating on the shares. The fim updated its model its announcement its PIPE-307…
Contineum, J&J's depression drug fails to meet mid-stage trial goal
Contineum Therapeutics said on Monday an experimental depression drug it developed with Johnson & Johnson failed to meet the main goal of a mid-stage study.
Contineum says MOONLIGHT-1 trial did not achieve its primary endpoint
The company states: “Contineum (CTNM) Therapeutics announced that the MOONLIGHT-1 trial did not achieve its primary efficacy endpoint. The trial evaluated improvement from baseline in the Montgomery-A...
Contineum down 11% atter MOONLIGHT-1 trial did not achieve endpoint
16:09 EDT Contineum (CTNM) down 11% atter MOONLIGHT-1 trial did not achieve endpoint
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for in...
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for in...
Contineum initiated with an Outperform at LifeSci Capital
LifeSci Capital initiated coverage of Contineum (CTNM) with an Outperform rating and $24 price target
Contineum reports Q2 EPS (40c), consensus (45c)
Cash, cash equivalents and marketable securities were $236.6 million as of June 30, 2026. Contineum (CTNM) believes its cash resources are sufficient to fund its planned operations through mid-2029. “...
Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for in...
Contineum Therapeutics Earnings release: Q2 2026
Contineum Therapeutics released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Contineum Therapeutics Quarterly report: Q2 2026
Contineum Therapeutics has published its Q2 2026 quarterly earnings report on July 30, 2026.
Contineum publishes manuscript on PIPE-791 in Journal of Medicinal Chemistry
Contineum (CTNM) Therapeutics announced the publication of a manuscript describing the discovery and characterization of PIPE-791 in the Journal of Medicinal Chemistry. The article, “Discovery of PIPE...
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Key focus is on advancing PIPE-791 in IPF, with phase II enrollment progressing and strong differentiation from competitors due to dosing convenience and safety. Additional programs in pain and MDD are advancing, supported by a robust financial position and strategic partnerships.
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...